Aeglea BioTherapeutics, Inc. License Agreements
12 Contracts & Agreements
- Amended and Restated Cell Line License Agreement, dated October 14, 2024, by and between the Company and WuXi Biologics (Hong Kong) Limited (Filed With SEC on October 15, 2024)
- IL-23 (SPY003) License Agreement, dated October 11, 2024, by and between the Company and Paragon Therapeutics, Inc (Filed With SEC on October 15, 2024)
- TL1A (SPY002) License Agreement, dated May 14 2024, by and between the Company and Paragon Therapeutics, Inc (Filed With SEC on August 7, 2024)
- 47 (SPY001) License Agreement, dated May 14, 2024, by and between the Company and Paragon Therapeutics, Inc (Filed With SEC on August 7, 2024)
- Cell Line License Agreement, effective June 20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on December 22, 2023)
- Cell Line License Agreement, effective June 20, 2022, by and between Paragon Therapeutics, Inc. and WuXi Biologics (Hong Kong) Limited (Filed With SEC on October 10, 2023)
- License and Supply Agreement, dated March 21, 2021, by and between the Registrant and Immedica Pharma AB (Filed With SEC on May 10, 2021)
- Amended and Restated Patent License Agreement No. PM1401501, dated January 31, 2017, between the Registrant and The University of Texas at Austin on behalf of the Board of Regents... (Filed With SEC on March 7, 2019)
- Amended and Restated Patent License Agreement No. PM1401501, dated January 31, 2017, between the Registrant and The University of Texas at Austin on behalf of the Board of Regents... (Filed With SEC on March 13, 2018)
- Amended and Restated Patent License Agreement Agreement No. PM1401501 (Filed With SEC on March 23, 2017)
- PATENT LICENSE AGREEMENT AGREEMENT NO. PM1401601 (Filed With SEC on September 14, 2015)
- PATENT LICENSE AGREEMENT AGREEMENT NO. PM1401601 (Filed With SEC on June 16, 2015)
